Genome Biology Division, New England Biolabs, Inc., Ipswich, MA 01938, USA.
Genome Biology Division, New England Biolabs, Inc., Ipswich, MA 01938, USA.
J Mol Biol. 2020 Sep 4;432(19):5304-5321. doi: 10.1016/j.jmb.2020.07.023. Epub 2020 Aug 5.
Chromatin accessibility is a predictor of gene expression, cell division, and cell type specificity. NicE-viewSeq (Nicking Enzyme-assisted viewing and Sequencing) allows accessible chromatin visualization and sequencing with overall lower mitochondrial DNA and duplicated sequences interference relative to ATAC-see. Using NicE-viewSeq, we interrogated the accessibility of chromatin in a cell cycle (G1, S, and G2/M)-specific manner using mammalian cells. Despite DNA replication and subsequent condensation of chromatin to chromosomes, chromatin accessibility remained generally preserved with minimal subtle alterations. Genome-wide alteration of chromatin accessibility within TSS and enhancer elements gradually decreased as cells progressed from G1 to G2M, with distinct differential accessibility near consensus transcription factors sites. Inhibition of histone deacetylases promoted accessible chromatin within gene bodies, correlating with apoptotic gene expression. In addition, reduced chromatin accessibility for the MYC oncogene pathway correlated with downregulation of pertinent genes. Surprisingly, repetitive RNA loci expression remained unaltered following histone acetylation-mediated increased accessibility. Therefore, we suggest that subtle changes in chromatin accessibility are a prerequisite during the cell cycle and histone deacetylase inhibitor-mediated therapeutics.
染色质可及性是基因表达、细胞分裂和细胞类型特异性的预测因子。NicE-viewSeq(切口酶辅助观察和测序)允许可视化和测序染色质的可及性,与 ATAC-see 相比,总体上降低了线粒体 DNA 和重复序列的干扰。使用 NicE-viewSeq,我们使用哺乳动物细胞以细胞周期(G1、S 和 G2/M)特异性的方式检测了染色质的可及性。尽管 DNA 复制和随后的染色质凝聚到染色体上,但染色质的可及性通常保持不变,只有微小的变化。随着细胞从 G1 到 G2M 的进展,TSS 和增强子元件中染色质可及性的全基因组改变逐渐减少,在共识转录因子位点附近存在明显的差异可及性。组蛋白去乙酰化酶的抑制促进了基因体内的可及染色质,与凋亡基因表达相关。此外,MYC 癌基因途径的染色质可及性降低与相关基因的下调相关。令人惊讶的是,组蛋白乙酰化介导的可及性增加后,重复 RNA 基因座的表达仍然没有改变。因此,我们认为,染色质可及性的细微变化是细胞周期和组蛋白去乙酰化酶抑制剂介导的治疗的先决条件。